How should respiratory syncytial virus (RSV) be treated in a 70-year-old patient?

RSV Treatment in a 70-Year-Old Patient

For a 70-year-old patient with active RSV infection, treatment remains primarily supportive care, as no specific antiviral therapy is approved or routinely recommended for older adults. 1, 2

Acute Management of Active RSV Infection

Supportive Care (Standard of Care)

• Provide symptomatic treatment including fluids, antipyretics, and oxygen supplementation when needed 1
• Monitor respiratory status closely, particularly for signs of respiratory distress or hypoxemia 2
• Assess for and manage exacerbations of underlying chronic conditions (heart failure, COPD, asthma), as RSV commonly triggers decompensation 3

Antiviral Therapy Considerations

• Ribavirin is the only licensed antiviral but is NOT routinely recommended for immunocompetent older adults 4, 5
• Aerosolized ribavirin may be considered for severe cases in immunocompromised patients only, particularly those with lower respiratory tract disease 2, 5
• Early therapy with ribavirin plus intravenous immunoglobulin has shown survival benefit specifically in immunocompromised persons 6
• Emerging fusion inhibitors, attachment inhibitors, and RNA synthesis inhibitors remain investigational 5

Clinical Monitoring

Common symptoms to monitor include cough, sputum production, fever, dyspnea, sore throat, and rhinorrhea 2. Older adults with RSV typically have underlying comorbidities that increase risk for pneumonia (10-20% in nursing homes) and death (2-5% in nursing homes) 6.

Prevention for Future Seasons

This 70-year-old patient should receive RSV vaccination to prevent future infections, as they fall within the age-based recommendation category. 3, 7

Vaccination Recommendations

• All adults aged 70-79 years should receive a single dose of RSV vaccine based on multiple international guidelines 3
• The CDC/ACIP recommends RSV vaccination for all adults ≥75 years, and for adults 60-74 years with risk factors 7
• European guidelines (Germany, Ireland, Italy, Spain) recommend vaccination for adults ≥60-75 years depending on country 3

Available Vaccines

Two protein subunit vaccines are available with proven efficacy 3:

RSVPreF3 (GSK Arexvy):

• Single intramuscular dose 3
• 93.8% efficacy against RSV-associated lower respiratory tract disease in adults aged 70-79 years (first season) 3
• 74.9% cumulative efficacy over 2 seasons in this age group 3
• 94.1% efficacy against severe disease (first season) 3

RSVpreF (Pfizer Abrysvo):

• Single intramuscular dose 3
• Similar efficacy profile with 62.5% efficacy in adults aged 70-79 years over 2 seasons 3

Real-World Vaccine Effectiveness

Recent data demonstrates strong real-world performance:

• 82.3% effectiveness against RSV-associated hospitalization in adults aged 75-79 years 8
• 75.1% overall effectiveness against acute respiratory infection in adults ≥60 years 9
• 86.7% effectiveness against severe disease requiring oxygen supplementation 8
• 88.6% effectiveness against lower respiratory tract infection including pneumonia 8
• 77.4% effectiveness against exacerbation of chronic lung disease 8
• 78.8% effectiveness against exacerbation of chronic heart disease, lung disease, and/or frailty 8

Safety Considerations

• Both vaccines are well-tolerated with acceptable safety profiles 3
• Important caveat: Post-licensure surveillance identified a small increased risk of Guillain-Barré syndrome (GBS) 7, 9, 10
  • RSVPreF: 18.2 excess GBS cases per million doses 3, 9, 10
  • RSVPreF3: 1.8 excess GBS cases per million doses 3
• Risk of myocarditis is NOT associated with RSV vaccines (this is specific to COVID-19 vaccines) 10
• No excess risk of immune thrombocytopenic purpura detected 9

Timing and Administration

• Vaccination should be administered as a single dose via intramuscular injection 3
• Ideally given before RSV season (typically fall/winter months) 3
• Can be co-administered with influenza and COVID-19 vaccines, though further data on interactions are emerging 3

Key Clinical Pitfalls

Common mistakes to avoid:

• Do NOT withhold vaccination based on lack of documented comorbidities—patient attestation is sufficient 7
• Do NOT use ribavirin routinely in immunocompetent older adults—reserve for immunocompromised patients with severe disease 4, 6, 5
• Do NOT assume RSV is only a pediatric disease—it causes approximately 10,000 deaths annually in US adults >64 years, comparable to non-pandemic influenza 4, 6
• Do NOT rely solely on viral culture or antigen detection for diagnosis in adults—these are insensitive; RT-PCR combined with serology offers best sensitivity 4, 6